JP2018504894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504894A5 JP2018504894A5 JP2017532639A JP2017532639A JP2018504894A5 JP 2018504894 A5 JP2018504894 A5 JP 2018504894A5 JP 2017532639 A JP2017532639 A JP 2017532639A JP 2017532639 A JP2017532639 A JP 2017532639A JP 2018504894 A5 JP2018504894 A5 JP 2018504894A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- car
- antibody
- nucleic acid
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 230000004068 intracellular signaling Effects 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 4
- 108700012439 CA9 Proteins 0.000 claims description 4
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims description 4
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims description 4
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 4
- 241000710831 Flavivirus Species 0.000 claims description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 4
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 241000315672 SARS coronavirus Species 0.000 claims description 4
- 102100035721 Syndecan-1 Human genes 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- -1 ICOS Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022011441A JP7548950B2 (ja) | 2014-12-19 | 2022-01-28 | キメラ抗原受容体およびその使用方法 |
| JP2024147204A JP2024163140A (ja) | 2014-12-19 | 2024-08-29 | キメラ抗原受容体およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094625P | 2014-12-19 | 2014-12-19 | |
| US62/094,625 | 2014-12-19 | ||
| US201562252083P | 2015-11-06 | 2015-11-06 | |
| US62/252,083 | 2015-11-06 | ||
| PCT/US2015/067225 WO2016100985A2 (en) | 2014-12-19 | 2015-12-21 | Chimeric antigen receptors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022011441A Division JP7548950B2 (ja) | 2014-12-19 | 2022-01-28 | キメラ抗原受容体およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018504894A JP2018504894A (ja) | 2018-02-22 |
| JP2018504894A5 true JP2018504894A5 (enExample) | 2019-02-07 |
Family
ID=55229842
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532639A Pending JP2018504894A (ja) | 2014-12-19 | 2015-12-21 | キメラ抗原受容体およびその使用方法 |
| JP2022011441A Active JP7548950B2 (ja) | 2014-12-19 | 2022-01-28 | キメラ抗原受容体およびその使用方法 |
| JP2024147204A Pending JP2024163140A (ja) | 2014-12-19 | 2024-08-29 | キメラ抗原受容体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022011441A Active JP7548950B2 (ja) | 2014-12-19 | 2022-01-28 | キメラ抗原受容体およびその使用方法 |
| JP2024147204A Pending JP2024163140A (ja) | 2014-12-19 | 2024-08-29 | キメラ抗原受容体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20170362297A1 (enExample) |
| EP (1) | EP3233900A2 (enExample) |
| JP (3) | JP2018504894A (enExample) |
| KR (1) | KR20170090506A (enExample) |
| CN (1) | CN108064252A (enExample) |
| AU (4) | AU2015364245B2 (enExample) |
| BR (1) | BR112017013176A2 (enExample) |
| CA (1) | CA2968412A1 (enExample) |
| IL (3) | IL320860A (enExample) |
| RU (1) | RU2017125531A (enExample) |
| WO (1) | WO2016100985A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107892719B (zh) * | 2012-10-04 | 2022-01-14 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| US9511092B2 (en) | 2013-01-28 | 2016-12-06 | St. Jude Children's Research Hospital, Inc. | Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease |
| EP3134111B1 (en) * | 2014-04-25 | 2022-06-08 | Dana-Farber Cancer Institute, Inc. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
| US10428305B2 (en) | 2014-05-15 | 2019-10-01 | National University Of Singapore | Modified natural killer cells that express IL15 and uses thereof |
| WO2015184099A1 (en) | 2014-05-28 | 2015-12-03 | 4-Antibody Ag | Anti-gitr antibodies and methods of use thereof |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| WO2017144681A1 (en) | 2016-02-25 | 2017-08-31 | Cell Medica Switzerland Ag | Binding members to pd-l1 |
| US11549099B2 (en) * | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| IL276515B2 (en) * | 2016-06-29 | 2025-11-01 | Checkpoint Therapeutics Inc | Pd-l1-specific antibodies and methods of using the same |
| ES3000676T3 (en) * | 2016-07-07 | 2025-03-03 | Iovance Biotherapeutics Inc | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
| US11077178B2 (en) | 2016-09-21 | 2021-08-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use |
| JP6887492B6 (ja) * | 2016-10-04 | 2021-07-14 | プレシジョン バイオサイエンシズ，インク． | 遺伝子改変細胞で使用するための共刺激ドメイン |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| EP3538551A4 (en) * | 2016-11-10 | 2020-11-11 | Fortis Therapeutics, Inc. | CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF |
| CN108148862B (zh) * | 2016-12-05 | 2019-03-08 | 上海优卡迪生物医药科技有限公司 | 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用 |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| AU2018246235B2 (en) | 2017-03-27 | 2023-12-21 | National University Of Singapore | Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CN110914289B (zh) | 2017-05-12 | 2024-05-14 | 克里斯珀医疗股份公司 | 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途 |
| CN107337736B (zh) * | 2017-06-06 | 2019-07-26 | 上海优卡迪生物医药科技有限公司 | Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用 |
| US12258381B2 (en) | 2018-02-09 | 2025-03-25 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| JP2021518104A (ja) * | 2018-03-14 | 2021-08-02 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 |
| WO2019193476A1 (en) | 2018-04-02 | 2019-10-10 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| JP2021521778A (ja) * | 2018-04-16 | 2021-08-30 | メモリアル スローン ケタリング キャンサー センター | Ｔ細胞枯渇、およびそれに関連する方法および組成物 |
| IL278348B2 (en) | 2018-05-11 | 2025-03-01 | Crispr Therapeutics Ag | Methods and preparations for treating cancer |
| US20210275589A1 (en) * | 2018-07-13 | 2021-09-09 | Nanjing Legend Biotech Co. Ltd. | Co-receptor systems for treating infectious diseases |
| WO2020020210A1 (zh) * | 2018-07-24 | 2020-01-30 | 科济生物医药（上海）有限公司 | 免疫效应细胞治疗肿瘤的方法 |
| US12486514B2 (en) | 2018-08-29 | 2025-12-02 | National University Of Singapore | Method to specifically stimulate survival and expansion of genetically-modified immune cells |
| JP7458382B2 (ja) | 2018-09-27 | 2024-03-29 | オートラス リミテッド | キメラ抗原受容体 |
| KR20210101255A (ko) * | 2018-11-26 | 2021-08-18 | 엔카르타, 인크. | 다중 면역 세포 유형의 동시 증폭을 위한 방법, 관련 조성물 및 암 면역요법에서 상기의 용도 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| US11104732B2 (en) * | 2019-04-24 | 2021-08-31 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune inhibition induced by SIGLEC-15 |
| CN114269777A (zh) * | 2019-04-26 | 2022-04-01 | 北卡罗来纳大学教堂山分校 | 嵌合抗原受体构建体及其在car-t细胞中的用途 |
| MX2021013359A (es) | 2019-04-30 | 2022-01-31 | Crispr Therapeutics Ag | Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19. |
| AU2020265679A1 (en) | 2019-04-30 | 2021-12-23 | Senti Biosciences, Inc. | Chimeric receptors and methods of use thereof |
| EP3983447A4 (en) | 2019-06-14 | 2023-06-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against muc1 and methods of use thereof |
| CN114286683B (zh) * | 2019-07-17 | 2024-10-01 | 新加坡国立大学 | 由免疫细胞合成和分泌的功能性结合物 |
| WO2021016606A1 (en) * | 2019-07-24 | 2021-01-28 | Eureka Therapeutics, Inc. | Chimeric antigen receptor t cells and uses thereof |
| WO2021113307A2 (en) * | 2019-12-02 | 2021-06-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-l1 and methods of use thereof |
| EP4431110A3 (en) * | 2020-01-19 | 2025-01-15 | Chineo Medical Technology Co., Ltd. | Enhanced receptor for improving immune cell function |
| WO2021225399A1 (ko) * | 2020-05-08 | 2021-11-11 | (주)에스엠티바이오 | 암 치료를 위한 키메라 항원 수용체 |
| CA3188728A1 (en) | 2020-08-07 | 2022-02-10 | Marc Nasoff | Immunoconjugates targeting cd46 and methods of use thereof |
| EP4291207A4 (en) * | 2021-02-11 | 2025-02-19 | The Trustees of The University of Pennsylvania | CCR4-TARGETED CHIMERIC ANTIGEN RECEPTOR CELL THERAPY |
| KR20220136876A (ko) | 2021-04-01 | 2022-10-11 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| IL299875B2 (en) * | 2021-04-12 | 2024-12-01 | Academia Sinica | Improved coronavirus vaccine |
| KR20220144000A (ko) | 2021-04-16 | 2022-10-26 | 주식회사 이뮤노로지컬디자이닝랩 | Programmed death-ligand 1(PD-L1)에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
| WO2022235940A1 (en) | 2021-05-06 | 2022-11-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
| KR20230089464A (ko) | 2021-12-13 | 2023-06-20 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| KR20230089462A (ko) | 2021-12-13 | 2023-06-20 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| JP2025508020A (ja) * | 2022-03-08 | 2025-03-21 | ヴァクセル－バイオ | Ｐｄ－ｌ１特異的キメラ抗原受容体及びそれを含む免疫細胞 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| WO2005060520A2 (en) | 2003-11-25 | 2005-07-07 | Dana-Farber Cancer Institute, Inc. | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF |
| CA2597717C (en) | 2005-02-18 | 2014-10-21 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
| US8466263B2 (en) | 2005-12-02 | 2013-06-18 | Dana-Farber Cancer Institute, Inc. | Carbonic anhydrase IX (G250) anitbodies |
| CN101970483A (zh) | 2007-12-06 | 2011-02-09 | 达纳-法伯癌症研究公司 | 抗流感病毒抗体及其使用方法 |
| WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| WO2011153380A2 (en) | 2010-06-02 | 2011-12-08 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| MX2013008376A (es) | 2011-01-18 | 2013-08-12 | Univ Pennsylvania | Composiciones y metodos para el tratamiento de cancer. |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| HK1203393A1 (en) * | 2012-04-11 | 2015-10-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| EP3511343A1 (en) | 2012-05-04 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| CN104583230A (zh) * | 2012-07-13 | 2015-04-29 | 宾夕法尼亚大学董事会 | 通过共同引入双特异性抗体增强car t细胞的活性 |
| CN107892719B (zh) * | 2012-10-04 | 2022-01-14 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| KR102363191B1 (ko) * | 2013-02-26 | 2022-02-17 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| US9822166B2 (en) | 2013-03-15 | 2017-11-21 | Dana-Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
| EP4043489A1 (en) | 2014-03-19 | 2022-08-17 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
| EP3134111B1 (en) | 2014-04-25 | 2022-06-08 | Dana-Farber Cancer Institute, Inc. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
| MX2017004311A (es) | 2014-10-03 | 2017-12-07 | Dana Farber Cancer Inst Inc | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. |
| EP3204418B1 (en) | 2014-10-06 | 2020-03-25 | Dana Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
| CN108064251A (zh) * | 2014-12-19 | 2018-05-22 | 达纳－法伯癌症研究所公司 | 碳酸酐酶ix特异性嵌合抗原受体及其使用方法 |
| WO2017075537A1 (en) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
-
2015
- 2015-12-21 KR KR1020177020045A patent/KR20170090506A/ko active Pending
- 2015-12-21 WO PCT/US2015/067225 patent/WO2016100985A2/en not_active Ceased
- 2015-12-21 IL IL320860A patent/IL320860A/en unknown
- 2015-12-21 RU RU2017125531A patent/RU2017125531A/ru not_active Application Discontinuation
- 2015-12-21 CA CA2968412A patent/CA2968412A1/en active Pending
- 2015-12-21 EP EP15828615.3A patent/EP3233900A2/en active Pending
- 2015-12-21 IL IL302660A patent/IL302660B2/en unknown
- 2015-12-21 BR BR112017013176-5A patent/BR112017013176A2/en not_active Application Discontinuation
- 2015-12-21 CN CN201580069023.0A patent/CN108064252A/zh active Pending
- 2015-12-21 JP JP2017532639A patent/JP2018504894A/ja active Pending
- 2015-12-21 US US15/537,779 patent/US20170362297A1/en not_active Abandoned
- 2015-12-21 AU AU2015364245A patent/AU2015364245B2/en active Active
- 2015-12-21 IL IL252295A patent/IL252295B2/en unknown
-
2020
- 2020-06-30 AU AU2020204373A patent/AU2020204373B2/en active Active
- 2020-08-06 US US16/986,913 patent/US12195514B2/en active Active
-
2022
- 2022-01-17 AU AU2022200257A patent/AU2022200257B2/en active Active
- 2022-01-28 JP JP2022011441A patent/JP7548950B2/ja active Active
-
2024
- 2024-01-31 AU AU2024200592A patent/AU2024200592A1/en active Pending
- 2024-08-29 JP JP2024147204A patent/JP2024163140A/ja active Pending
- 2024-12-05 US US18/970,194 patent/US20250243259A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504894A5 (enExample) | ||
| RU2017125531A (ru) | Химерные антигенные рецепторы и способы их применения | |
| HRP20240357T1 (hr) | Stanica | |
| WO2019090003A9 (en) | Chimeric antigen receptors specific for b-cell maturation antigen (bcma) | |
| FI3896091T3 (fi) | BCMA:han kohdentuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| JP2020114264A5 (enExample) | ||
| JP2018500337A5 (enExample) | ||
| HRP20191839T1 (hr) | Car ekspresijski vektor i t stanice koje eksprimiraju car | |
| JP2019527557A5 (enExample) | ||
| JP2016508518A5 (enExample) | ||
| BR112018008442A2 (pt) | receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados | |
| MX2014010183A (es) | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. | |
| HK1252235A1 (zh) | 表达γ-δT细胞受体(TCR)和嵌合抗原受体(CAR)的T细胞 | |
| ZA201607060B (en) | Drug related transgene expression | |
| JP2017529851A5 (enExample) | ||
| WO2017147383A8 (en) | Modified cells for immunotherapy | |
| EP4477748A3 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| WO2016109410A3 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| JP2017513478A5 (enExample) | ||
| FI4219687T3 (fi) | Menetelmiä immuunisolupopulaatioiden eristämiseksi, viljelemiseksi ja geneettiseksi muokkaamiseksi adoptiivista terapiaa varten | |
| RU2018140056A (ru) | Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена | |
| WO2011130491A3 (en) | Methods and compositions for treating hiv | |
| WO2023150698A3 (en) | Chimeric ilt receptor compositions and methods | |
| IL274806B1 (en) | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof | |
| MX2021015967A (es) | Receptor de antigeno quimerico con dominio coestimulador 4-1bb. |